Dynavax Technologies entered into research collaboration and license agreement with AstraZeneca to discover and develop toll-like receptor (TLR)-9 agonist-based therapies for treating asthma and chronic and obstructive pulmonary disease (COPD). The deal could be worth up to US$136 M to Dynavax.